Aspire BioPharma (ASBP) Financials

Balance sheets

Sep 1, 2024Jun 1, 2024Dec 1, 2023Sep 1, 2023Jun 1, 2023

Total Assets

$184.0 K(-96.4%)$5.1 M(+10850.0%)$46.2 K--

Current Assets

$184.0 K(+271.0%)$49.6 K(+7.4%)$46.2 K--

Non Current Assets

$0.0(-100.0%)$5.0 M(+100.0%)$0.0--

Total Liabilities

$985.6 K(-78.7%)$4.6 M(+764.6%)$534.0 K--

Current Liabilities

$985.6 K(+28.9%)$764.3 K(+43.1%)$534.0 K--

Long Term Liabilities

$0.0(-100.0%)$3.9 M(+100.0%)$0.0--

Shareholders Equity

-$801.6 K(-281.4%)$442.0 K(+190.6%)-$487.9 K--

Book Value

-$801.6 K(-281.4%)$442.0 K(+190.6%)-$487.9 K--

Working Capital

-$801.6 K(-12.2%)-$714.7 K(-46.5%)-$487.8 K--

Cash And Cash Equivalents

$16.5 K(-15.8%)$19.6 K(+75.0%)$11.2 K--

Accounts Payable

$129.4 K(-19.9%)$161.5 K(-6.5%)$172.8 K--

Accounts Receivable

-----

Short Term Debt

$853.1 K(+91.5%)$445.4 K(+23.5%)$360.6 K--

Long Term Debt

-----

Total Debt

$853.1 K(+91.5%)$445.4 K(+23.5%)$360.6 K(+100.0%)$0.0(0%)$0.0

Debt To Equity

-1.1(-204.9%)1.0(+236.5%)-0.7--

Current Ratio

0.2(+216.7%)0.1(-33.3%)0.1--

Quick Ratio

-----

Inventory

-----

Retained Earnings

-$2.0 M(-13.6%)-$1.8 M(-22.3%)-$1.5 M--

PB Ratio

-----

Income statements

Sep 1, 2024Jun 1, 2024Dec 1, 2023Sep 1, 2023Jun 1, 2023

EPS

-$0.0(-152.4%)-$0.0(-23.5%)-$0.0(-21.4%)-$0.0(+30.0%)-$0.0

TTM EPS

-$0.0(-75.0%)-$0.0(-2.0%)-$0.0(-50.0%)-$0.0(-70.0%)-$0.0

Revenue

-----

TTM Revenue

-----

Total Expenses

$242.6 K(+150.4%)$96.9 K(+27.0%)$76.3 K(+16.5%)$65.5 K(-27.5%)$90.3 K

Operating Expenses

$242.6 K(+150.4%)$96.9 K(+27.0%)$76.3 K(+16.5%)$65.5 K(-27.5%)$90.3 K

Cost Of Goods Sold

-----

TTM Cost Of Goods Sold

-----

Gross Profit

$0.0(0%)$0.0(0%)$0.0(0%)$0.0(0%)$0.0

TTM Gross Profit

$0.0(0%)$0.0(0%)$0.0(0%)$0.0(0%)$0.0

Gross Margin

-----

Operating Profit

-$242.6 K(-150.4%)-$96.9 K(-27.0%)-$76.3 K(-16.5%)-$65.5 K(+27.5%)-$90.3 K

TTM Operating Profit

-$415.8 K(-74.2%)-$238.7 K(-2.8%)-$232.1 K(-49.0%)-$155.8 K(-72.5%)-$90.3 K

Operating Margin

-----

Net Income

-$243.6 K(-151.4%)-$96.9 K(-26.2%)-$76.8 K(-17.3%)-$65.5 K(+27.5%)-$90.3 K

TTM Net Income

-$417.3 K(-74.5%)-$239.2 K(-2.8%)-$232.6 K(-49.3%)-$155.8 K(-72.5%)-$90.3 K

Net Margin

-----

EBIT

-$242.6 K(-150.4%)-$96.9 K(-27.0%)-$76.3 K(-16.5%)-$65.5 K(+27.5%)-$90.3 K

TTM EBIT

-$415.8 K(-74.2%)-$238.7 K(-2.8%)-$232.1 K(-49.0%)-$155.8 K(-72.5%)-$90.3 K

EBITDA

-$242.6 K(-150.4%)-$96.9 K(-27.0%)-$76.3 K(-16.5%)-$65.5 K(+27.5%)-$90.3 K

TTM EBITDA

-$415.8 K(-74.2%)-$238.7 K(-2.8%)-$232.1 K(-49.0%)-$155.8 K(-72.5%)-$90.3 K

Selling, General & Administrative Expenses

$235.6 K(+172.7%)$86.4 K(+31.3%)$65.8 K(+29.5%)$50.8 K(-36.3%)$79.8 K

TTM SGA

$387.8 K(+91.0%)$203.0 K(+3.4%)$196.4 K(+50.4%)$130.6 K(+63.7%)$79.8 K

Depreciation And Amortization

$0.0(0%)$0.0-$0.0(0%)$0.0

TTM D&A

$0.0(0%)$0.0-$0.0(0%)$0.0

Interest Expense

$0.0(0%)$0.0(0%)$0.0(0%)$0.0(0%)$0.0

TTM Interest Expense

$0.0(0%)$0.0(0%)$0.0(0%)$0.0(0%)$0.0

Income Tax

$1000.0(+100.0%)$0.0(-100.0%)$500.0(+100.0%)$0.0(0%)$0.0

TTM Income Tax

$1500.0(+200.0%)$500.0(0%)$500.0(+100.0%)$0.0(0%)$0.0

PE Ratio

-----

PS Ratio

-----

Cashflow statements

Sep 1, 2024Jun 1, 2024Dec 1, 2023Sep 1, 2023Jun 1, 2023

Cash From Operations

-$744.8 K(-253.0%)-$211.0 K--$254.3 K(-629.8%)$48.0 K

TTM CFO

-$955.8 K(-105.4%)-$465.3 K--$206.3 K(-529.8%)$48.0 K

Cash From Investing

$0.0(+100.0%)-$38.3 K-$0.0(+100.0%)-$38.3 K

TTM CFI

-$38.3 K(0%)-$38.3 K--$38.3 K(0%)-$38.3 K

Cash From Financing

$750.1 K(+191.2%)$257.6 K-$268.8 K(+100.0%)$0.0

TTM CFF

$1.0 M(+91.4%)$526.4 K-$268.8 K(+100.0%)$0.0

Free Cash Flow

-$744.8 K(-198.9%)-$249.2 K--$254.3 K(-2694.9%)$9800.0

TTM FCF

-$994.0 K(-97.4%)-$503.5 K--$244.5 K(-2594.9%)$9800.0

CAPEX

-----

TTM CAPEX

-----

Dividends Paid

-----

TTM Dividends Paid

-----

TTM Dividend Per Share

-----

TTM Dividend Yield

-----

Payout Ratio

-----